Merck KGaA, GSK pen $4.2B biobucks pact for next-gen Bavencio

This entry was posted by Joyce Wells on February 5, 2019 at 6:32 pm

Merck KGaA, GSK pen $4.2B biobucks pact for next-gen Bavencio

…have on the lives of cancer patients.”Dr. Belén Garijo, CEO Healthcare of Merck KGaA, added, “Our bifunctional fusion protein M7824 has the potential to bring new answers to patients living with…

Click here to read the full article
7
Like
Save

Comments

Write a comment

*

summary